In August 2025, Eli Lilly and Company announced positive topline results from the Phase III ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes
Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, et al
WellaFreeze 360 is equipped with multiple applicators, allowing several areas to be treated simultaneously within the same session block
Aggregation causes peptides to clump and lose biological activity
Low potassium symptoms include muscle cramps , weakness, constipation , heart palpitations, and fatigue
What happens now The five-year BALANCE program will be delayed, but that doesn't mean that Medicare beneficiaries will lose weight-loss drug coverage